Modulation of binding strength in several classes of active site inhibitors of acetylcholinesterase studied by comparative binding energy analysis.

The comparative binding energy (COMBINE) methodology has been used to identify the key residues that modulate the inhibitory potencies of three structurally different classes of acetylcholinesterase inhibitors (tacrines, huprines, and dihydroquinazolines) targeting the catalytic active site of this enzyme. The extended set of energy descriptors and the partial least-squares methodology used by COMBINE analysis on a unique training set containing all the compounds yielded an interpretable model that was able to fit and predict the activities of the whole series of inhibitors reasonably well (r2 = 0.91 and q2 = 0.76, 4 principal components). A more robust model (q2 = 0.81 and SDEP = 0.25, 3 principal components) was obtained when the same chemometric analysis was applied to the huprines set alone, but the method was unable to provide predictive models for the other two families when they were treated separately from the rest. This finding appears to indicate that the enrichment in chemical information brought about by the inclusion of different classes of compounds into a single training set can be beneficial when an internally consistent set of pharmacological data can be derived. The COMBINE model was externally validated when it was shown to predict the activity of an additional set of compounds that were not employed in model construction. Remarkably, the differences in inhibitory potency within the whole series were found to be finely tuned by the electrostatic contribution to the desolvation of the binding site and a network of secondary interactions established between the inhibitor and several protein residues that are distinct from those directly involved in the anchoring of the ligand. This information can now be used to advantage in the design of more potent inhibitors.

[1]  F. J. Luque,et al.  New tacrine-huperzine A hybrids (huprines): highly potent tight-binding acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease. , 2000, Journal of medicinal chemistry.

[2]  F. Gago,et al.  Identification of a putative binding site for [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptase. , 2001, Journal of medicinal chemistry.

[3]  F. J. Luque,et al.  Synthesis, in vitro pharmacology, and molecular modeling of very potent tacrine-huperzine A hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease. , 1999, Journal of medicinal chemistry.

[4]  B. Honig,et al.  A rapid finite difference algorithm, utilizing successive over‐relaxation to solve the Poisson–Boltzmann equation , 1991 .

[5]  M Pastor,et al.  Comparative binding energy (COMBINE) analysis of human neutrophil elastase inhibition by pyridone-containing trifluoromethylketones. , 2001, Combinatorial chemistry & high throughput screening.

[6]  Hugo Verli,et al.  Design, synthesis, and pharmacological profile of novel fused pyrazolo[4,3-d]pyridine and pyrazolo[3,4-b][1,8]naphthyridine isosteres: a new class of potent and selective acetylcholinesterase inhibitors. , 2003, Journal of medicinal chemistry.

[7]  A. Cavalli,et al.  SAR of 9-amino-1,2,3,4-tetrahydroacridine-based acetylcholinesterase inhibitors: synthesis, enzyme inhibitory activity, QSAR, and structure-based CoMFA of tacrine analogues. , 2000, Journal of medicinal chemistry.

[8]  J L Sussman,et al.  X-ray structures of Torpedo californica acetylcholinesterase complexed with (+)-huperzine A and (-)-huperzine B: structural evidence for an active site rearrangement. , 2002, Biochemistry.

[9]  A. Castro,et al.  Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease. , 2001, Mini reviews in medicinal chemistry.

[10]  D Lamba,et al.  Three‐dimensional structure of a complex of galanthamine (Nivalin®) with acetylcholinesterase from Torpedo californica: Implications for the design of new anti‐Alzheimer drugs , 2001, Proteins.

[11]  A. Ortiz,et al.  Assessment of solvation effects on calculated binding affinity differences: trypsin inhibition by flavonoids as a model system for congeneric series. , 1997, Journal of medicinal chemistry.

[12]  M. Emmerling,et al.  Differentiation and distribution of acetylcholinesterase molecular forms in the mouse cochlea , 1988, Hearing Research.

[13]  P. C. Hariharan,et al.  The influence of polarization functions on molecular orbital hydrogenation energies , 1973 .

[14]  R C Wade,et al.  Nuclear receptor-DNA binding specificity: A COMBINE and Free-Wilson QSAR analysis. , 2000, Journal of medicinal chemistry.

[15]  R. Wade,et al.  Prediction of drug binding affinities by comparative binding energy analysis , 1995 .

[16]  L. Schneider,et al.  A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. , 2003, Current drug targets.

[17]  A. Cavalli,et al.  Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 2. Role of the substituents on the phenyl ring and nitrogen atoms of caproctamine. , 2003, Journal of medicinal chemistry.

[18]  P. Taylor,et al.  Expression of recombinant acetylcholinesterase in a baculovirus system: kinetic properties of glutamate 199 mutants. , 1992, Biochemistry.

[19]  K. Sharp,et al.  Calculating the electrostatic potential of molecules in solution: Method and error assessment , 1988 .

[20]  Luhua Lai,et al.  Further development and validation of empirical scoring functions for structure-based binding affinity prediction , 2002, J. Comput. Aided Mol. Des..

[21]  J. Briggs,et al.  ON THE MECHANISM OF ACETYLCHOLINESTERASE ACTION : THE ELECTROSTATICALLY INDUCED ACCELERATION OF THE CATALYTIC ACYLATION STEP , 1997 .

[22]  C. Lipinski,et al.  Physical parameters for brian uptake: optimizing log P, log D and pKa of T H A , 1991 .

[23]  Marta Murcia,et al.  Virtual screening with flexible docking and COMBINE-based models. Application to a series of factor Xa inhibitors. , 2004, Journal of medicinal chemistry.

[24]  F. J. Luque,et al.  Rational design of reversible acetylcholinesterase inhibitors. , 2002, Mini reviews in medicinal chemistry.

[25]  Jirí Damborský,et al.  Comparative binding energy analysis of haloalkane dehalogenase substrates: Modelling of enzyme-substrate complexes by molecular docking and quantum mechanical calculations , 2003, J. Comput. Aided Mol. Des..

[26]  N. Inestrosa,et al.  Acetylcholinesterase promotes the aggregation of amyloid-beta-peptide fragments by forming a complex with the growing fibrils. , 1997, Journal of molecular biology.

[27]  Federico Gago,et al.  Chemometrical identification of mutations in HIV-1 reverse transcriptase conferring resistance or enhanced sensitivity to arylsulfonylbenzonitriles. , 2004, Journal of the American Chemical Society.

[28]  P. Kollman,et al.  A well-behaved electrostatic potential-based method using charge restraints for deriving atomic char , 1993 .

[29]  B. A. Luty,et al.  Discovering high-affinity ligands from the computationally predicted structures and affinities of small molecules bound to a target: A virtual screening approach , 2000 .

[30]  Zoran Radić,et al.  Structural insights into ligand interactions at the acetylcholinesterase peripheral anionic site , 2003, The EMBO journal.

[31]  C. J. Moore,et al.  The synthesis and in vitro acetylcholinesterase and butyrylcholinesterase inhibitory activity of tacrine (Cognex®) derivaties , 1992 .

[32]  J. Sussman,et al.  Reaction Products of Acetylcholinesterase and VX Reveal a Mobile Histidine in the Catalytic Triad , 1999 .

[33]  Ferran Sanz,et al.  3D-QSAR methods on the basis of ligand–receptor complexes. Application of COMBINE and GRID/GOLPE methodologies to a series of CYP1A2 ligands , 2000, J. Comput. Aided Mol. Des..

[34]  N. Ariel,et al.  Structures of recombinant native and E202Q mutant human acetylcholinesterase complexed with the snake-venom toxin fasciculin-II. , 2000, Acta crystallographica. Section D, Biological crystallography.

[35]  J. Sussman,et al.  Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. , 1999, Structure.

[36]  Yuan-Ping Pang,et al.  Acetylcholinesterase complexed with bivalent ligands related to huperzine a: experimental evidence for species-dependent protein-ligand complementarity. , 2003, Journal of the American Chemical Society.

[37]  W. Foye,et al.  Principles of medicinal chemistry , 1974 .

[38]  Wolfgang Sippl,et al.  Design, Synthesis, and Structure—Activity Relationships of a Series of 3‐[2‐(1‐Benzylpiperidin‐4‐yl)ethylamino]pyridazine Derivatives as Acetylcholinesterase Inhibitors. , 2001 .

[39]  Johan Åqvist,et al.  Ligand binding affinity prediction by linear interaction energy methods , 1998, J. Comput. Aided Mol. Des..

[40]  Ajay,et al.  Computational methods to predict binding free energy in ligand-receptor complexes. , 1995, Journal of medicinal chemistry.

[41]  Peter A. Kollman,et al.  FREE ENERGY CALCULATIONS : APPLICATIONS TO CHEMICAL AND BIOCHEMICAL PHENOMENA , 1993 .

[42]  M Pastor,et al.  Comparative binding energy analysis of HIV-1 protease inhibitors: incorporation of solvent effects and validation as a powerful tool in receptor-based drug design. , 1998, Journal of medicinal chemistry.

[43]  A Caflisch,et al.  Computational ligand design. , 1999, Combinatorial chemistry & high throughput screening.

[44]  K. Courtney,et al.  A new and rapid colorimetric determination of acetylcholinesterase activity. , 1961, Biochemical pharmacology.

[45]  J. Sussman,et al.  Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[46]  P. Kollman,et al.  A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules , 1995 .

[47]  R. Wade,et al.  Prediction of drug binding affinities by comparative binding energy analysis. , 1997, Journal of medicinal chemistry.

[48]  F. J. Luque,et al.  3D structure of Torpedo californica acetylcholinesterase complexed with huprine X at 2.1 A resolution: kinetic and molecular dynamic correlates. , 2002, Biochemistry.

[49]  G. Klebe,et al.  Knowledge-based scoring function to predict protein-ligand interactions. , 2000, Journal of molecular biology.

[50]  R. Wade,et al.  Comparative binding energy (COMBINE) analysis of influenza neuraminidase-inhibitor complexes. , 2001, Journal of medicinal chemistry.

[51]  F. J. Luque,et al.  Predicting relative binding free energies of tacrine-huperzine A hybrids as inhibitors of acetylcholinesterase. , 1999, Journal of medicinal chemistry.

[52]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[53]  R C Wade,et al.  Comparative binding energy analysis of the substrate specificity of haloalkane dehalogenase from Xanthobacter autotrophicus GJ10. , 2001, Biochemistry.

[54]  A. Goldman,et al.  Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein , 1991, Science.